Related Experiment Video
Updated: May 26, 2026
08:20
In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol
Published on: December 30, 2016
CD4(+)Foxp3(+) regulatory T cell therapy in transplantation
Qizhi Tang1, Jeffrey A Bluestone, Sang-Mo Kang
1Division of Transplantation, Department of Surgery, University of California San Francisco, San Francisco, CA 94143-0780, USA. qizhi.tang@ucsfmedctr.org
Journal of Molecular Cell Biology
|December 16, 2011
Summary
Regulatory T cells (Tregs) show promise for treating autoimmune diseases and preventing transplant rejection. Research is advancing Treg therapy for human clinical trials, focusing on safety and efficacy in transplantation.
Area of Science:
- Immunology
- Cell Therapy
- Transplantation Science
Background:
- Regulatory T cells (Tregs) are crucial for immune homeostasis, suppressing immune responses in an antigen-specific manner.
- Tregs have demonstrated efficacy in preclinical models for autoimmune diseases and alloimmunity, including graft-versus-host disease and organ transplantation.
- Extensive research into Treg biology and preclinical efficacy has paved the way for human clinical trials.
Purpose of the Study:
- To review the development of therapeutic strategies using CD4(+)Foxp3(+) Tregs for transplantation.
- To highlight studies informing clinical approaches for Treg cell therapy in transplant recipients.
- To address the challenges and risks associated with Treg therapy in clinical settings.
Main Methods:
- Review of preclinical and clinical studies on Treg cell therapy in transplantation.
- Analysis of Treg biology and mechanisms of immune suppression.
- Evaluation of strategies to optimize Treg therapy for safety and efficacy.
Main Results:
- Tregs offer long-term protection against autoimmune conditions in mouse models.
- Tregs effectively suppress alloimmunity in models of transplantation and graft-versus-host disease.
- Current research focuses on translating preclinical Treg findings into human clinical applications.
Conclusions:
- Treg cell therapy holds significant potential for managing immune responses in transplantation.
- Clinical translation requires careful consideration of safety, efficacy, and optimization strategies.
- Further research is essential to overcome challenges and maximize the benefits of Treg therapy for transplant patients.
